Form 4: Beam Therapeutics SVP Sells Shares to Cover Tax Obligations

Sentiment:

SEC Form 4 Filing


Bethany J. Cavanagh, SVP of Finance and Treasurer at Beam Therapeutics, sold 3,015 shares of common stock on April 1, 2025, to cover tax withholding obligations.

Summary

  • On April 1, 2025, Bethany J. Cavanagh, the SVP of Finance and Treasurer at Beam Therapeutics, sold 3,015 shares of common stock.
  • The sale was executed at a weighted average price of $18.3516 per share, with individual transactions ranging from $17.76 to $18.38.
  • This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units.
  • The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on August 9, 2024.
  • Following the transaction, Cavanagh directly owns 44,512 shares of Beam Therapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't reflect a significant change in the executive's outlook on the company.

Industry Context

This is a routine Form 4 filing, reflecting an insider's stock sale to cover tax obligations, a common practice among executives with equity compensation. It doesn't necessarily indicate a change in the executive's confidence in the company.

Stakeholder Impact

  • The transaction is unlikely to have a significant impact on stakeholders as it is a routine sale to cover tax obligations.

Key Dates

DateDescription
March 31, 2021Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
March 31, 2022Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
March 31, 2023Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
March 31, 2024Date of restricted stock unit grant under the Beam Therapeutics Inc. 2019 Equity Incentive Plan.
August 9, 2024Date the Rule 10b5-1 trading plan was adopted by the Reporting Person.
April 1, 2025Date of the transaction (stock sale).
April 3, 2025Date of the Form 4 filing.

Keywords

Beam Therapeutics, Insider Trading, Form 4, Stock Sale, Tax Withholding, Rule 10b5-1, Equity Incentive Plan, Cavanagh, BEAM

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.